title: Hepatoprotective effect of pioglitazone in cases of chemotherapy induced steatohepatitis.
abstract: OBJECTIVE
  To evaluate the harmful effects of 5-floururacil (5-FU) and Irinotecan on the liver and to determine the role of Pioglitazone in averting liver damage.
  
  
  METHODS
  Sixty Sprague-Dawley female rats were divided into 4 groups. The first group (n=20) was administered 40 mg of 5-FU and 40 mg kg of Irinotecan intraperitoneally for 4 cycles, while the second group (n=20) received 4 mg kg of Pioglitazone by gastric gavage at 5 days a week for 20 days in addition to chemotherapy. The third group (n=10) was the sham group; chemotherapy regimen was given as in the first group. In addition, normal saline was given daily for 20 days by gastric gavage. The fourth group (n=10) was only given a standard diet as a control group. Then, blood samples were studied for the evaluation of alanine aminotransferase (AST)and alanine aminotransferase (ALT) levels. And left liver lobes of rats were taken for pathological analysis.
  
  
  RESULTS
  Although short-term chemotherapy was administered,aminotransferase (AST) and alanine aminotransferase (ALT)levels were found to be significantly higher in the first and third groups compared to the others (p 0.0001). No significant difference was determined between the second and the control group. Pioglitazone reduced the adverse metabolic effects of chemotherapy on the liver, but had no effect on the histopathological changes.
  
  
  CONCLUSIONS
  short-term CT causes metabolic disruption in hepatocytes, but not relevant with CASH. Preventive treatments like Pioglitazone should be used more carefully.
authors: S
authors: S
authors: Celik
authors: K
authors: K
authors: Kartal
authors: H
authors: H
authors: Ozseker
authors: M
authors: M
authors: Hayran
authors: E
authors: E
authors: Hamaloglu
mesh_terms: D000410:Alanine Transaminase / Q000097:blood; D000818:Animals; D000964:Antimetabolites, Antineoplastic / Q000009:adverse effects; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000009:adverse effects*; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects; D001219:Aspartate Aminotransferases / Q000097:blood; D015415:Biomarkers / Q000097:blood; D002166:Camptothecin / Q000009:adverse effects / Q000031:analogs & derivatives; D005234:Fatty Liver / Q000139:chemically induced / Q000201:enzymology / Q000517:prevention & control*; D005260:Female; D005472:Fluorouracil / Q000009:adverse effects; D000077146:Irinotecan; D008099:Liver / Q000187:drug effects*; D008106:Liver Cirrhosis, Experimental / Q000139:chemically induced / Q000188:drug therapy* / Q000201:enzymology; D000077205:Pioglitazone; D020011:Protective Agents / Q000494:pharmacology*; D051381:Rats; D017207:Rats, Sprague-Dawley; D045162:Thiazolidinediones / Q000494:pharmacology*; D016896:Treatment Outcome
chemical_list: D000964:Antimetabolites, Antineoplastic; D000970:Antineoplastic Agents; D000972:Antineoplastic Agents, Phytogenic; D015415:Biomarkers; D020011:Protective Agents; D045162:Thiazolidinediones; D000077146:Irinotecan; D001219:Aspartate Aminotransferases; D000410:Alanine Transaminase; D005472:Fluorouracil; D000077205:Pioglitazone; D002166:Camptothecin